SEPTEMBER 2019 STUDY: Provisional, All Stages/All Types
Detailed Study Description
According to Cancer.gov, this year more than an estimated 1,735,350 new cases of cancer will be diagnosed in the United States and 609,640 people will die from the disease. The most common cancers (listed in descending order according to estimated new cases in 2018) are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. The number of new cases of cancer (cancer incidence) is 439.2 per 100,000 men and women per year (based on 2011–2015 cases). The number of cancer deaths (cancer mortality) is 163.5 per 100,000 men and women per year (based on 2011–2015 deaths). Cancer mortality is higher among men than women (196.8 per 100,000 men and 139.6 per 100,000 women). When comparing groups based on race/ethnicity and sex, cancer mortality is highest in African American men (239.9 per 100,000) and lowest in Asian/Pacific Islander women (88.3 per 100,000).
The Agency for Healthcare research and Quality (AHRQ) estimates that the direct medical costs (total of all health care costs) for all types of cancer in the US in 2015 were $80.2 billion. This year, about 609,640 Americans are expected to die of cancer – that’s more than 1,670 people a day. Cancer is the second most common cause of death in the US, exceeded only by heart disease.
The VIDA Center (Santa Teresa, Costa Rica) employs a novel approach of combining several evidence based adjunct therapies in the treatment of cancer. Through the combination of several Diet and Lifestyle Interventions, improved sleep, and psychosocial support strategies, participants are educated and challenged to eliminate behaviors and environmental exposures that are considered high risk, correlative or even likely causative to the development of cancer. Participants receive 12 weeks of high touch health coaching and attend 3 weeks at a wellness center located in Costa Rica. This approach avoids pharmacological treatment and allows for a reproducible methods with achievable ‘at home’ adherence compared to existing non conventional treatments.
The VIDA Center therapeutic system consists of a proprietary program that applies 7 distinctive, yet interconnected Epigenetic therapies (changes that affect gene activity and expression). These non toxic therapies appear to support the human body’s natural ability to manage a variety of diseases including cancer. The 7 therapies incorporate nutrigenomics, microbiomics, lifestyle stress reduction, exercise, social support, and emotional wellbeing. The application of these therapies has been effective in individual patient treatment. For the purposes of this study, the investigators will be using all seven therapies in a small group setting, over a fixed period of time. Participants will measured for a wide variety of health and cancer markers at the beginning and at the end of the 12 week program.
Study Type: Practice Based Observational
Estimated Enrollment: 5-10 participants
Official Title: First Looks at the Effect of Diet and Lifestyle Interventions on a variety of cancer types and stages
General Inclusion: Pathology or Imaging confirmed diagnosis, all ages, all stages, medically stable.
General Exclusion: High degree of difficulty with pain management, medical complications requiring hospital environment, chronic or severe ascites.
Actual Study Start Date: September 1st, 2019
Estimated Primary Completion Date: December15th, 2020
Estimated Study Completion Date: January15, 2021
Sanjevani Integrative Medicine Health and Lifestyle Center
Information provided by (Responsible Party):